Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
FDA Approves Pulmicort Respules
September 3rd, 2000
The U.S. Food and Drug Administration has approved Pulmicort Respules (budesonide inhalation suspension) for asthma in children between the ages of one to eight. Pulmicort Respules is the first anti-inflammatory corticosteroid formulated for inhalation using a nebulizer in this age group. Previously, no other inhaled corticosteroid has been approved for use in children younger than four years of age. This approval allows for treatment with an approved formulation in a significant, currently unserved pediatric asthma population, according to the agency. Inhaled corticosteroids when used as maintenance therapy are effective in reducing the...
Source: Medical Letter on the CDC & FDA (2000-09-03)
|
